Non-coated multiparticulate matrix systems for colon targeting

References

• Ashford MT, Fell J, Attwood D, Sharma H, Woodhead P. (1993a). An evaluation of pectin as a carrier for drug targeting to the colon. J Controlled Release, 26:213–220.
   Web of Science ®Google Scholar
• Watts PJ, Illum L. (1997). Colonic drug delivery. Drug Dev Ind Pharm, 23:893–913.
   Web of Science ®Google Scholar
• Friend DR. (2005). New oral delivery systems for treatment of inflammatory bowel disease. Adv Drug Deliv Rev, 57:247–265.
   PubMed Web of Science ®Google Scholar
• Yang L, Chu JS, Fix JA. (2002). Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation. Int J Pharm, 235:1–15.
   PubMed Web of Science ®Google Scholar
• Semdé R, Moës AJ, Devleeschouwer MJ, Amighi K. (2003). Synthesis and enzymatic degradation of epichlorohydrin cross-linked pectins. Drug Dev Ind Pharm, 29:203–213.
   PubMed Web of Science ®Google Scholar
• Klotz U. (2005). Colonic targeting of aminosalicylates for the treatment of ulcerative colitis. Dig Liver Dis, 37:381–388.
   PubMedGoogle Scholar
• Onishi H, Oosegi T, Machida Y, McGinity JW. (2005). Preparation and in vitro evaluation of chitosan microspheres containing prednisolone: comparison of simple and conjugate microspheres. Drug Dev Ind Pharm, 31:597–605.
   PubMed Web of Science ®Google Scholar
• Karrout Y, Neut C, Wils D, Siepmann F, Deremaux L, Desreumaux P, Siepmann J. (2009a). Characterization of ethylcellulose:starch-based film coatings for colon targeting. Drug Dev Ind Pharm, 35:1190–1200.
   PubMed Web of Science ®Google Scholar
• Karrout Y, Neut C, Siepmann F, Wils D, Ravaux P, Deremaux L, Flament M-P, Dubreuil L, Lemdani M, Desreumaux L, Siepmann J. (2010). Enzymatically degraded Eurylon 6 HP-PG: ethylcellulose film coatings for colon targeting in inflammatory bowel disease patients. J Pharm Pharmacol, 62:1676–1684.
   PubMed Web of Science ®Google Scholar
• Zhao W, Song L, Deng H, Yao H. (2009). Hydration, erosion, and release behavior of guar-based hydrophilic matrix tablets containing total alkaloids of Sophora alopecuroides. Drug Dev Ind Pharm, 35:594–602.
   PubMed Web of Science ®Google Scholar
• Ashford MT, Fell J, Attwood D, Woodhead P. (1993b). An in vitro investigation into the suitability of pH-dependent polymers for colonic targeting. Int J Pharm, 91:241–245.
   Web of Science ®Google Scholar
• Rudolph MW, Klein S, Beckert TE, Petereit H, Dressman JB. (2001). A new 5-aminosalicylic acid multi-unit dosage form for the therapy of ulcerative colitis. Eur J Pharm Biopharm, 51:183–190.
   PubMed Web of Science ®Google Scholar
• McConnell EL, Short MD, Basit AW. (2008a). An in vivo comparison of intestinal pH and bacteria as physiological trigger mechanisms for colon targeting in man. J Controlled Release, 130:154–160.
   PubMed Web of Science ®Google Scholar
• Klotz U, Maier KE, Fischer C, Bauer KH. (1985). A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics. Arzneimittelforschung, 35:636–639.
   PubMed Web of Science ®Google Scholar
• Leopold CS, Eikeler D. (2000). Basic coating polymers for the colon-specific drug delivery in inflammatory bowel disease. Drug Dev Ind Pharm, 26:1239–1246.
   PubMed Web of Science ®Google Scholar
• Ibekwe VC, Fadda HM, Parsons GE, Basit AW. (2006). A comparative in vitro assessment of the drug release performance of pH-responsive polymers for ileo-colonic delivery. Int J Pharm, 308:52–60.
   PubMed Web of Science ®Google Scholar
• Van den Mooter G, Samyn C, Kinget R. (1995). In vivo evaluation of a colon-specific drug delivery system: an absorption study of theophylline from capsules coated with azo polymers in rats. Pharm Res, 12:244–247.
   PubMed Web of Science ®Google Scholar
• Siew LF, Basit AW, Newton JM. (2000). The potential of organic-based amylose-ethylcellulose film coatings as oral colon-specific drug delivery systems. AAPS Pharmscitech, 1:E22, 53–61.
   PubMedGoogle Scholar
• Shibata N, Ohno T, Shimokawa T, Hu Z, Yoshikawa Y, Koga K et al. (2001). Application of pressure-controlled colon delivery capsule to oral administration of glycyrrhizin in dogs. J Pharm Pharmacol, 53:441–447.
   PubMed Web of Science ®Google Scholar
• Mulder CJ, Tytgat GN, Weterman IT, Dekker W, Blok P, Schrijver M et al. (1988). Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Gastroenterology, 95:1449–1453.
   PubMed Web of Science ®Google Scholar
• Miner P, Hanauer S, Robinson M, Schwartz J, Arora S. (1995). Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. Dig Dis Sci, 40:296–304.
   PubMed Web of Science ®Google Scholar
• Ibekwe VC, Fadda HM, McConnell EL, Khela MK, Evans DF, Basit AW. (2008). Interplay between intestinal pH, transit time and feed status on the in vivo performance of pH responsive ileo-colonic release systems. Pharm Res, 25:1828–1835.
   PubMed Web of Science ®Google Scholar
• McConnell EL, Fadda HM, Basit AW. (2008b). Gut instincts: explorations in intestinal physiology and drug delivery. Int J Pharm, 364:213–226.
   PubMed Web of Science ®Google Scholar
• Karrout Y, Neut C, Wils D, Siepmann F, Deremaux L, Dubreuil L et al. (2009b). Colon targeting with bacteria-sensitive films adapted to the disease state. Eur J Pharm Biopharm, 73:74–81.
   PubMed Web of Science ®Google Scholar
• Karrout Y, Neut C, Wils D, Siepmann F, Deremaux L, Desreumaux P et al. (2009c). Novel polymeric film coatings for colon targeting: how to adjust desired membrane properties. Int J Pharm, 371:64–70.
   PubMed Web of Science ®Google Scholar
• Karrout Y, Neut C, Wils D, Siepmann F, Deremaux L, Flament MP et al. (2009d). Novel polymeric film coatings for colon targeting: Drug release from coated pellets. Eur j Pharm Sci, 37:427–433.
   PubMed Web of Science ®Google Scholar
• Van den Heuvel EG, Wils D, Pasman WJ, Bakker M, Saniez MH, Kardinaal AF. (2004). Short-term digestive tolerance of different doses of Nutriose FB, a food dextrin, in adult men. Eur J Clin Nutr, 58:1046–1055.
   PubMed Web of Science ®Google Scholar
• van den Heuvel EG, Wils D, Pasman WJ, Saniez MH, Kardinaal AF. (2005). Dietary supplementation of different doses of NUTRIOSE FB, a fermentable dextrin, alters the activity of faecal enzymes in healthy men. Eur J Nutr, 44:445–451.
   PubMed Web of Science ®Google Scholar
• Pasman WJ, Wils D, Saniez MH, Kardinaal AFM. (2006). Long-term gastrointestinal tolerance of Nutriose FB in healthy men. Eur J Clin Nutr, 60:1024–1034.
   PubMed Web of Science ®Google Scholar
• Krishnaiah YS, Veer Raju P, Dinesh Kumar B, Bhaskar P, Satyanarayana V. (2001). Development of colon targeted drug delivery systems for mebendazole. J Control Release, 77:87–95.
   PubMed Web of Science ®Google Scholar
• Amrutkar JR, Gattani SG. (2009). Chitosan-chondroitin sulfate based matrix tablets for colon specific delivery of indomethacin. AAPS Pharmscitech, 10:670–677.
   PubMed Web of Science ®Google Scholar
• De Brabander C, Vervaet C, Fiermans L, Remon JP. (2000). Matrix mini-tablets based on starch/microcrystalline wax mixtures. Int J Pharm, 199:195–203.
   PubMed Web of Science ®Google Scholar
• Hamdani J, Moës AJ, Amighi K. (2002). Development and evaluation of prolonged release pellets obtained by the melt pelletization process. Int J Pharm, 245:167–177.
   PubMed Web of Science ®Google Scholar
• Zambito Y, Baggiani A, Carelli V, Serafini MF, Di Colo G. (2005). Matrices for site-specific controlled-delivery of 5-fluorouracil to descending colon. J Control Release, 102:669–677.
   PubMed Web of Science ®Google Scholar
• Qasim A, Seery J, O’Morain CA. (2001). 5-Aminosalicylates in inflammatory bowel disease: choosing the right dose. Dig Liver Dis, 33:393–398.
   PubMedGoogle Scholar
• Frieri G, Pimpo M, Galletti B, Palumbo G, Corrao G, Latella G et al. (2005). Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis. Dig Liver Dis, 37:92–96.
   PubMedGoogle Scholar
• Travis SP, Stange EF, Lémann M, Oresland T, Bemelman WA, Chowers Y et al.; for the European Crohn’s and Colitis Organisation (ECCO). (2008). European evidence-based Consensus on the management of ulcerative colitis: Current management. J Crohns Colitis, 2:24–62.
   PubMed Web of Science ®Google Scholar
• Kellens M, Meeussen W, Gehrke R, Reynaers H. (1991). Synchrotron radiation investigations of the polymorphic transitions of saturated monoacid triglycerides. Part 1: Tripalmitin and tristearin. Chem Phys Lipids, 58:131–144.
   Web of Science ®Google Scholar
• Hamdani J, Moës AJ, Amighi K. (2003). Physical and thermal characterisation of Precirol and Compritol as lipophilic glycerides used for the preparation of controlled-release matrix pellets. Int J Pharm, 260:47–57.
   PubMed Web of Science ®Google Scholar
• Tozaki H, Komoike J, Tada C, Maruyama T, Terabe A, Suzuki T, Yamamoto A, Muranishi S. (1997). Chitosan capsules for colon-specific drug delivery: improvement of insulin absorption from the rat colon. J Pharm Sci, 86:1016–1021.
   PubMed Web of Science ®Google Scholar
• Tozaki H, Odoriba T, Okada N, Fujita T, Terabe A, Suzuki T et al. (2002). Chitosan capsules for colon-specific drug delivery: enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats. J Control Release, 82:51–61.
   PubMed Web of Science ®Google Scholar
• Lorenzo-Lamosa ML, Remuñán-López C, Vila-Jato JL, Alonso MJ. (1998). Design of microencapsulated chitosan microspheres for colonic drug delivery. J Control Release, 52:109–118.
   PubMed Web of Science ®Google Scholar